Evidence map›Paper›PMID 39586010›Full record

ArticleOcular immunology and inflammation2025

Vitamin D Supplementation and Remission from Chronic Anterior Uveitis.

Hueyjong Shih, Yineng Chen, Katie Huynh, Eric B Suhler, Jennifer E Thorne, Nirali P Bhatt, C Stephen Foster, Douglas A Jabs, Grace A Levy-Clarke, Robert B Nussenblatt and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Ocular immunology and inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Hueyjong ShihDepartment of Ophthalmology and Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
Yineng ChenDepartment of Ophthalmology and Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Katie HuynhDepartment of Ophthalmology and Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
Eric B SuhlerDepartment of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
Jennifer E ThorneWilmer Eye Institute, Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Nirali P BhattDepartment of Ophthalmology, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
C Stephen FosterMassachusetts Eye Research and Surgery Institution, Waltham, Massachusetts, USA.ORCID 0000-0002-6612-5653
Douglas A JabsWilmer Eye Institute, Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Grace A Levy-ClarkeDepartment of Ophthalmology and Visual Sciences, West Virginia University, Morgantown, West Virginia, USA.
Robert B NussenblattLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
James T RosenbaumDepartment of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
H Nida SenDepartment of Ophthalmology, George Washington University, Washington, District of Columbia, USA.
Sapna S GangaputraVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Abhishek R PayalMahatme Eye Bank Eye Hospital, Nagpur, Maharashtra, India.
Hosne BegumWilmer Eye Institute, Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Naira KhachatryanDepartment of Ophthalmology, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sherri-Ann M Burnett-BowieEndocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Gui-Shuang YingDepartment of Ophthalmology and Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
John H KempenDepartment of Ophthalmology and Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.ORCID 0000-0002-2967-4792
Lucia SobrinDepartment of Ophthalmology and Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.

Funding

Scientific TransparencyP30EY001583 · NEI · UNIVERSITY OF PENNSYLVANIA · PI Qi N Cui · 1985 to 2026
$19.5M
Long-term Follow-up of the Systemic Immunosuppressive Therapy for Eye Diseases CohortR01EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2004 to 2025
$8.1M
NEI NIH HHS P30 EY001583NEI NIH HHS R01 EY014943
6 · The paper itself

Abstract

purposeChronic anterior uveitis (CAU) often requires suppressive therapy, which has potential side effects including cataract, ocular hypertension, and increased risk of infection. No remittive therapy is currently available; however, several studies have demonstrated an association between low 25-hydroxy Vitamin D (25OHD) levels and either uveitis incidence or uveitis disease activity. This study investigates the potential of Vitamin D supplementation as a remittive treatment for CAU.

methodsWe conducted a retrospective analysis using data from the Systemic Immunosuppressive Therapy for Eye Disease (SITE) cohort study, which included patients with ocular inflammatory disease seen at U.S. tertiary centers between 1979 and 2010. Vitamin D supplementation data was analyzed for patients with CAU. Eyes were considered in remission if they remained quiet for at least 90 days off all anti-inflammatory treatment for eye disease.

resultsAmong 2688 patients who never used Vitamin D, the cumulative adjusted CAU remission incidence was 13.5% at the 16-month follow-up. In contrast, among 75 patients who used Vitamin D for a duration of ≤1 year, the cumulative adjusted CAU remission incidence was 28% at 16 months. The use of Vitamin D was associated with a crude hazard ratio for remission of 2.14 [95% confidence interval (CI) 1.23-3.71,

conclusionIn the SITE Cohort, Vitamin D supplementation is associated with a significantly increased incidence of remission. Vitamin D supplementation should be explored in a prospective trial as the next step of evaluation.

Indexed as

Dietary SupplementsUveitis, AnteriorVitamin DVitaminsAdultAgedChronic DiseaseFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedRemission InductionRetrospective Studies25-hydroxyvitamin DVitamin DVitaminsChronic anterior uveitisremissionVitamin D

Identifiers

PMID39586010
PMCPMC12037315

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.